Equities

Sareum Holdings PLC

Sareum Holdings PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)4.15
  • Today's Change-0.05 / -1.19%
  • Shares traded3.07m
  • 1 Year change+104.94%
  • Beta-0.3744
Data delayed at least 20 minutes, as of Jan 21 2022 16:13 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of GBP
(except for per share items)
Fiscal data as of Jun 30 2021202120202019
ASSETS
Cash And Short Term Investments2.691.800.92
Total Receivables, Net0.320.140.24
Total Inventory------
Prepaid expenses0.040.050.05
Other current assets, total------
Total current assets3.052.001.21
Property, plant & equipment, net0.000.000
Goodwill, net------
Intangibles, net------
Long term investments0.030.000.03
Note receivable - long term------
Other long term assets------
Total assets3.082.001.24
LIABILITIES
Accounts payable0.100.040.08
Accrued expenses0.030.090.05
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.160.070.01
Total current liabilities0.280.200.15
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities0.280.200.15
SHAREHOLDERS EQUITY
Common stock0.830.810.72
Additional paid-in capital171513
Retained earnings (accumulated deficit)(15)(14)(13)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity2.801.801.09
Total liabilities & shareholders' equity3.082.001.24
Total common shares outstanding3,3333,2422,876
Treasury shares - common primary issue000
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.